Hoth Therapeutics, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Hoth Therapeutics, Inc. reported a significant increase in net loss for 2025, alongside a going concern warning from its auditors, despite progress in its clinical pipeline and substantial capital raises.
NASDAQ
Hoth Therapeutics restates prior financial statements due to material errors in R&D expense recognition, while continuing to advance its pipeline and seek new opportunities.
NASDAQ
10-K: Hoth Therapeutics Issues Warrants and Files Annual Report, Outlines Financials and Future Plans
Hoth Therapeutics details a warrant agreement and its 2023 financial results, highlighting ongoing clinical trials and future development plans.